



The Oncology Institute Expands Florida Presence with Lakeland Clinic, Physician Dispensary

February 16, 2022 1:30 PM EST

Expansion into Polk County Adds the 54th Clinic Location for the Practice

LAKELAND, Fla., Feb. 16, 2022 (GLOBE NEWSWIRE) -- The Oncology Institute of Hope and Innovation (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, opened its 54th clinic location, and its sixth in Florida, in Lakeland on Monday. This expansion into Polk County comes on the heels of TOI's recently launched Florida physician dispensary and blood transfusion program, allowing TOI patients convenient access to oral chemotherapeutics and clinic-based blood product transfusions.

"We are excited to bring our cutting-edge cancer care to the residents of Polk County," shared Dr. Daniel Virnich, COO. "By expanding our footprint and service offerings, we are demonstrating our investment in the Florida market and elevating the standard of care in the communities we serve."

Patients at the [Lakeland, FL](#) clinic, located at 4730 Exploration Avenue, will be treated by [Dr. Syed Mahmood](#) and [Amber Madrid, NP](#) with [Dr. Kamal Sharma](#) joining the practice in June 2022. They will benefit from the same comprehensive services offered at all TOI locations, including: in-house lab, outpatient transfusions, and a state-of-the-art website with scheduling and patient portal capabilities. With the opening of the Florida dispensary, TOI patients will also benefit from the convenience of this service.

"Drs. Mahmood and Sharma are well-respected for their experience, skill, and compassion," added Dr. Virnich. "Their expertise will offer a huge benefit to patients in Polk County seeking hematology and oncology care."

About The Oncology Institute

Founded in 2007, The Oncology Institute of Hope and Innovation (TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of more than 1.5 million patients including clinical trials, stem cell transplants, transfusions, and other care delivery models traditionally associated with the most advanced healthcare organizations. With 80+ employed clinicians and more than 600 teammates in 54 clinic locations and growing, TOI is changing oncology for the better. For more information visit www.theoncologyinstitute.com.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "expect," "should," "would," "plan," "predict," "potential," "seem," "seek," "future," "outlook," and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding projections, estimates and forecasts of revenue and other financial and performance metrics and projections of market opportunity and expectations. These statements are based on various assumptions and on the current expectations of The Oncology Institute and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as, and must not be relied on by any investor as, a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of The Oncology Institute. These forward-looking statements are subject to a number of risks and uncertainties, including the outcome of judicial and administrative proceedings to which The Oncology Institute may become a party or governmental investigations to which The Oncology Institute may become subject that could interrupt or limit The Oncology Institute's operations, result in adverse judgments, settlements or fines and create negative publicity; changes in The Oncology Institute's clients' preferences, prospects and the competitive conditions prevailing in the healthcare sector; the risk that any required regulatory approvals could adversely affect the combined company; failure to continue to meet stock exchange listing standards; the impact of COVID-19 on The Oncology Institute's business; those factors discussed in the documents of The Oncology Institute filed, or to be filed, with the SEC. If the risks materialize or assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that The Oncology Institute presently know or currently believe are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect The Oncology Institute's expectations, plans or forecasts of future events and views as of the date of this press release. The Oncology Institute anticipate that subsequent events and developments will cause The Oncology Institute's assessments to change. The Oncology Institute do not undertake any obligation to update any of these forward-looking statements. These forward-looking statements should not be relied upon as representing The Oncology Institute's assessments as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Contacts

Media

The Oncology Institute
Julie Korinke
juliekorinke@theoncologyinstitute.com
(562) 735-3226 x 88806

Revive
Michael Petrone
mpetrone@reviveagency.com
(615) 760-4542

Investors

Solebury Trout

Maria Lycouris

investors@theoncologyinstitute.com